Objective: Hypercalcemia of malignancy (HCM) is caused by one of five known mechanisms -systemic release of ectopically synthesized parathyroid hormone related protein (PTHrP), calcitriol, parathyroid hormone (PTH), cytokines/chemokines or destruction of bone by osteolytic metastases. We report the first case of two simultaneous mechanisms for HCM in a patient with peripheral nerve sheath tumor (PNST) Methods: A PubMed and Google Scholar search was performed using 'hypercalcemia of malignancy'. Results: A 26-year-old woman with neurofibromatosis presented with worsening left hip pain. MRI showed a large left para-spinal mass, subtotal resection of which confirmed PNST. Despite chemoradiation therapy, the tumor progressed over 16 months, requiring tumor debulking and L3-4 lumbar laminectomy. The patient developed progressive bilateral lower extremity weakness due to direct tumor invasion of lumbosacral vertebrae with concurrent hypercalcemia. Ionized calcium was 1.47 mmol/dL(0.95-1.32 mmol/dL), PTH <4.0 pg/mL(8-85 pg/mL), 25-hydroxyvitamin D 14 ng/mL, calcitriol <8.0 pg/mL(18-78 pg/mL), PTHrP 40 pg/mL(14-27 pg/mL), urinary calcium <2.0 mg/24 hours, serum Ctelopeptide 1,008 pg/mL(64-640 pg/mL), bone specific alkaline phosphatase 15.7 mcg/L(4.7-17.8 mcg/L) with normal serum magnesium, phosphorus, creatinine. Intravenous zoledronic acid and hydration resulted in a normal ionized calcium. Additional imaging revealed extensive tumor invasion ofL3-S1
Introduction
Hypercalcemia of malignancy (HCM) is a paraneoplastic syndrome that is associated with a poor prognosis. Parathyroid-related protein (PTHrP) induced and osteolytic mechanisms account for 99% of HCM (1) with calcitriol and cytokine/chemokine induced disease responsible for 1% of the remaining cases. PTHrP-induced hypercalcemia has been described in solid malignancies; most commonly in squamous cell carcinoma. Osteolytic metastases are commonly observed in multiple myeloma but have also been described in breast and lung tumors. To our knowledge, paraneoplastic hypercalcemia due to PTHrP and osteolytic metastatic bone disease has not been previously described with malignant PNST.
Clinical Presentation
A 26-year-old Caucasian woman, with a past medical history significant for chronic hypertension and neurofibromatosis, initially presented to the hospital with a four-month history of worsening left hip pain and proximal weakness. She was unaware of any family history of calcium disorders or nephrolithiasis and had been taking a calcium-channel blocker for hypertension. Magnetic resonance imaging (MRI) of the lumbar spine revealed a large left-sided lumbar para-spinal mass with a biopsy of the mass exhibiting low cellularity and scattered atypical spindle cells. Immunohistochemistry of the tumor cells stained negative for CD34, CD99, SMA, desmin, Dog-1, P57, GFAP and CD57 and positive for S-100.
The patient underwent subtotal resection of the mass with pathology confirming malignant PNST, followed by chemotherapy and proton beam radiation therapy. Sixteen months after the initial admission for tumor resection, the patient was found on surveillance MRI to have increasing size of the same mass with new extension into L3 and L4 neural foramina. She was admitted a second time and underwent lumbar laminectomy and facectomy with intra-and extradural tumor debulking. Within a month of the second admission, the patient was readmitted a third time for progressive bilateral lower extremity weakness. MRI revealed a residual re-enlarging mass eroding the left lateral aspects of L4, L5, and S1 DOI:10.4158/ACCR-2019-0567 © 2020 AACE. vertebral bodies. At this time, she was also noted to have hypercalcemia with an ionized calcium of 1.47 mmol/dL (0.95-1.32 mmol/dL), a suppressed PTH of <4.0 pg/mL (8-85 pg/mL), 25-hydroxy Vitamin D of 14 ng/mL (optimal >30 ng/mL), and normal serum magnesium, phosphorus, creatinine, and serum protein electrophoresis. Urinary calcium revealed undetectable calcium of <2.0 mg/24 hours confirmed on repeat testing. Bone resorption marker, serum C-telopeptide (sCTx) was elevated 1008 pg/mL (64-640 pg/mL) whereas bone formation marker, bone specific alkaline phosphatase (BSAP) was normal at 15.7 mcg/L (4.7-17.8 mcg/L). With aggressive intravenous (IV) hydration and administration of IV zoledronic acid 4 mg, the ionized calcium normalized over the ensuing three days to 1.17 mmol/L. Results of further testing revealed an elevated PTHrP of 40 pg/mL (14-27 pg/mL) and suppressed calcitriol level of <8.0 pg/mL (18- 78 pg/mL). A Technetium-99 bone scan was negative for bone lesions. CT imaging revealed tumor invasion of the vertebral bodies of L5-S1 which was also confirmed on MRI, thereby confirming the presence of purely osteolytic tumor involvement of the vertebral bodies. After extensive interdisciplinary discussion with the patient, no further chemo-or radiation therapy was initiated. The patient was discharged with home hospice services.
Discussion
Hypercalcemia of malignancy (HCM) is a paraneoplastic manifestation of advanced cancer with 50% mortality within the first two months of the HCM diagnosis (1) . HCM may be caused by either humoral calcium transfer to breast milk, and as a local regulator in bone during fracture repair (5) . Both PTH and PTHrP mediate their actions through the parathyroid hormone 1 receptor (PTH1R). The actions of PTHrP in the kidney generally parallel those of PTH with both peptides directly stimulating tubular reabsorption of calcium (6) . Although PTH increases renal proximal tubular activation of 1-α-hydroxylation with subsequent synthesis of calcitriol and active calcium absorption, PTHrP has a much lessened effect on synthesis of 1,25-(OH)2D (5) . In human studies utilizing quantitative bone histomorphometry and biochemical markers of bone turnover, patients with PTHrP related-HHM have increased generalized bone resorption but do not have the usual coupled increase in osteoblastic bone formation as typically observed in primary hyperparathyroidism (7) . This is the most plausible explanation for the observed elevation of An uncommon mechanism for HCM is excessive 1,25-(OH)2D production by tumor cells or macrophages (calcitriol-induced hypercalcemia) accounting for less than 1% of cases. Excessive serum levels of active 1,25-(OH)2D increase intestinal calcium absorption beyond physiologic requirements and may contribute to enhanced bone resorption (12) . Rarer humoral causes for HCM include the synthesis of elevated serum levels of ectopic PTH or cytokines and/or chemokines by tumor. Cytokine/chemokine induced HCM induces systemic bone resorption without evidence of OMRH and normal concurrent serum levels of PTHrP, calcitriol, and PTH (13) . A phenomenon of mild elevation of total corrected calcium with normal ionized calcium levels, or 'pseudo-hypercalcemia' due to abnormal calcium binding by paraproteins has also been described (14) . A summary of the known mechanisms of HCM with their associated cancers was recently published by one of our authors and is updated in Table 1 (3).
Hypercalcemia of malignancy resulting from multiple mechanisms has been previously described.
A combination of calcitriol and PTHrP-induced HCM, has been described in rare cases of HTLV-1 positive ATLL, neuroendocrine tumors of the pancreas, seminoma, and ovarian carcinoma (3).
Cytokine/chemokine induced HCM has been described in conjunction with PTHrP or OMRH in multiple myeloma and breast cancer (2, 3, 7) . The combined mechanisms of OMRH and PTHrP induced HCM has been best described in breast cancer for the reasons described above with PTHrP being both a local skeletal tumor microenvironment mediator of osteolysis and causing systemic bone resorption. PTHrp is elevated in the serum of up to 50% of patients with breast cancer metastases to bone. The aforementioned combined mechanisms have not been described in conjunction with PNST. Although HCM has been reported in conjunction with rhabdomyosarcomas and gastrointestinal stromal tumors, both of which can be associated with neurofibromatosis-1, our patient did not have any evidence of these malignancies on magnetic resonance imaging or histopathology.
Treatment of hypercalcemia of malignancy is directed at targeting the underlying malignancy as well as effectively treating the underlying mechanism for hypercalcemia such as inhibiting bone resorption with bisphosphonates and denosumab, increasing urinary calcium excretion with intravenous saline, loop diuretics, and prednisone, decreasing intestinal calcium absorption and decreasing serum levels of 1,25-OHD with prednisone , and suppressing synthesis of PTH with calcimimetics (15) . More recently, the successful use of calcimimetics in PTHrP-mediated hypercalcemia has been described in case reports, through a mechanism yet to be fully elucidated (15) (16) (17) . In murine parathyroidectomized models, cinacalcet decreased calcium in a dose dependent manner without altering PTHrP levels; increased calcitonin secretion appears to play a role (18) . Another potential target for treatment that is yet to be tested in humans is the use of PTHrP-blocking antibodies. In murine models, this has led to resolution of HCM and improvement of cachexia (19) . The use of bone markers, urine calcium, and appropriate imaging can facilitate clarification of simultaneous multiple mechanisms underlying HCM (Table 2 ) and the selection of the most efficacious treatment for HCM. In our patient, zoledronate, a bisphosphonate, was effective in treating hypercalcemia resulting from excessive bone resorption from both her osteolytic bone lesions as well as PTHrP induced systemic resorption.
Conclusion
PTHrP induced hypercalcemia has been described in several solid malignancies; most commonly in squamous cell carcinoma. Osteolytic metastases are usually seen in multiple myeloma but have been described in breast and lung tumors. However, neither mechanism has been independently described in association with malignant PNST. Our patient had evidence of both mechanisms as the causation of hypercalcemia as documented by (i) an elevated PTHrP, low calcitriol, the absence of any urinary calcium confirmed on repeat testing, and (ii) presence of tumor invasion of bone on CT imaging, absence of osteoblastic lesions on a Tc-99 bone scan, and isolated elevation of sCTx consistent with purely osteolytic metastases. To our knowledge, paraneoplastic hypercalcemia resulting from the interplay of these mechanisms has not been previously described with PNST, and should be considered in the differential diagnosis of hypercalcemia in patients with this diagnosis. In patients with HCM it is important to
